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A previous study suggested an association of the single nucleotide polymorphism (SNP)
rs72796353 (IVS4+10 A>C) in the NOD2 gene with susceptibility to Crohn’s disease
(CD). However, this finding has not been confirmed. Given that NOD2 variants still repre-
sent the most important predictors for CD susceptibility and phenotype, we evaluated the
association of rs72796353 with inflammatory bowel disease (IBD) susceptibility and the
IBD phenotype.
Methodology
Genomic DNA from 2256 Caucasians, including 1073 CD patients, 464 patients with ulcera-
tive colitis (UC), and 719 healthy controls, was genotyped for the NOD2 SNP rs72796353
and the three main CD-associated NOD2mutations rs2066844, rs2066845, and
rs2066847. Subsequently, IBD association and genotype-phenotype analyses were
conducted.
Results
In contrast to the strong associations of the NOD2 SNPs rs2066844 (p=3.51 x 10-3),
rs2066845 (p=1.54 x 10-2), and rs2066847 (p=1.61 x 10-20) with CD susceptibility, no sig-
nificant association of rs72796353 with CD or UC susceptibility was found. However, in
CD patients without the three main CD-associated NOD2mutations, rs72796353 was
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significantly associated with the development of perianal fistulas (p=2.78 x 10-7, OR 5.27,
[95% CI 2.75-10.12] vs. NOD2 wild-type carriers).
Conclusion/Significance
Currently, this study represents the largest genotype-phenotype analysis of the impact of
the NOD2 variant rs72796353 on the disease phenotype in IBD. Our data demonstrate that
in CD patients the IVS4+10 A>C variant is strongly associated with the development of peri-
anal fistulas. This association is particularly pronounced in patients who are not carriers of
the three main CD-associated NOD2mutations, suggesting rs72796353 as additional
genetic marker for the CD disease behaviour.
Introduction
The two major forms of inflammatory bowel disease (IBD) Crohn’s disease (CD) and ulcerative
colitis (UC) are characterized by a chronic and relapsing intestinal inflammation caused by a
disrupted epithelial barrier integrity, probably due to an exaggerated inflammatory response to
the luminal microbiota [1]. Epidemiological observations from IBD families, twin studies,
cohort studies, and genome-wide association studies (GWAS) led to the identification of
numerous IBD susceptibility genes [2],[3],[4]. Nucleotide-binding oligomerization domain 2
(NOD2, GeneID: 64127), the first CD gene identified, gave rise to the hypothesis that the host’s
genetic background is one key factor that crucially influences the mucosal response to the lumi-
nal microbiota, and may lead to an aberrant, pathogenic immune response [5]. GWAS identi-
fied a total of 163 IBD susceptibility loci, including IL23R, ATG16L1, and IRGM [4,6–10].
Among these loci, the three NOD2mutations rs2066844, rs2066845, and rs2066847 still repre-
sent the strongest genetic predictors of CD susceptibility and phenotype [4].
In clinical practice, NOD2 represents the most important genetic predictor of the CD dis-
ease course, which is heterogeneous and progresses differently among patients. Epidemiologi-
cal data have shown that within 20 years, up to 90% of CD patients will experience either a
penetrating or a fistulizing disease phenotype, often necessitating intensive medical treatment
or surgery [11]. Early identification of a rapid progression of the disease would help to initiate
an active treatment at an early disease stage to modulate the course of CD. In previous geno-
type-phenotype correlations, we and others could demonstrate a significant association of the
three main NOD2mutations with ileal involvement, a stricturing phenotype and an early dis-
ease onset in CD patients [5,12–20].
In 2002, a French group published an analysis of the NOD2 gene by direct DNA sequencing
in 453 patients with CD, including 166 sporadic and 287 familial cases, 159 patients with ulcer-
ative colitis (UC), and 103 healthy control subjects[13]. A total of 67 sequence variations were
identified, and the three main NOD2 mutations (p.Arg702Trp, p.Gly908Arg, and p.
Leu1007fsX1008) were confirmed to be independently associated with CD susceptibility. In
addition, 27 rare variants were identified as potential disease-causing mutations, including the
NOD2 SNP rs72796353 (IVS4+10 A>C) [13].
In the study by Lesage et al. [13], the NOD2 SNP rs72796353 was only found in CD patients,
suggesting a potential role in CD development [13]. Apart from that, data on this SNP located
in the intervening sequence of exon 4 are very limited [21,22] and there are no data analysing
the phenotypic consequences of this SNP in IBD patients. Therefore, we aimed to analyse the
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association of the NOD2 SNP rs72796353 regarding diseases susceptibility and disease pheno-
type in a large, well-characterized German IBD cohort (n = 2256).
Patients and Methods
Ethical Statement
All individuals gave their written, informed consent prior to the study. The study was approved
by the local Ethics committee (Ludwig-Maximilians-University Munich) and adhered to the
ethical principles for medical research involving human subjects of the Helsinki Declaration.
Study population
A total of 2256 individuals were enrolled in this study, including a total of 1537 IBD patients of
Caucasian origin (1073 CD patients and 464 UC patients) as well as 719 healthy, unrelated
controls. All IBD patients were recruited from the University Hospital Munich-Grosshadern,
while the 719 controls were recruited from the University Hospital Munich-Innenstadt.
Patients with indeterminate colitis were excluded from the study. All individuals gave their
written, informed consent prior to the study. Phenotypic parameters were collected blindly to
the results of the genotype analysis and included demographic and clinical data (behaviour and
anatomic location of IBD, disease-related complications, surgical or immunosuppressive ther-
apy). Two senior gastroenterologists analysed the data which were recorded by patient charts
analysis and a detailed questionnaire based on an interview at the time of enrolment. The diag-
nosis of CD and UC was based on established international guidelines, using endoscopic,
radiological, and histopathological parameters [23]. CD patients were classified according to
the Montreal classification [24] including age at diagnosis (A), location (L), and behaviour (B)
of disease. In patients with UC, anatomic location was also assessed in accordance to the Mon-
treal classification based on the criteria ulcerative proctitis (E1), left-sided UC (distal UC; E2),
and extensive UC (pancolitis; E3). The demographic characteristics of the IBD study popula-
tion are summarized in Table 1.
DNA extraction and NOD2 genotyping
Genomic DNA was isolated from peripheral blood leukocytes and amplification of NOD2
exons 4, 8 and 11 was performed by standard procedures. Primers used for PCR amplification
of NOD2 exons 4, 8, and 11 are listed in the S1 Table. Sequences were analysed on an ABI
PRISM 377 DNA Sequencer (Applied Biosystems) using the Sequence Analysis program ver-
sion 3.4.5 (Applied Biosystems). Control subject and patient sequence data were compared to
the published NOD2 sequence, and all differences were documented. Primers used for DNA
sequence analysis of NOD2 exons 4, 8, and 11 are listed in S2 Table.
Statistical analyses
Each genetic marker was tested for Hardy-Weinberg equilibrium in the control population.
Single-marker allelic tests were performed with Pearson’s χ2 test. All tests were two-tailed and
p-values< 0.05 were considered significant. Odds ratios were calculated for the minor allele at
each SNP. For evaluation of phenotypic consequences, we conducted logistic regression analy-
ses. Data and haplotype analyses were done by using the Plink v1.07 software (http://pngu.
mgh.harvard.edu/purcell/plink/[25] and R-2.4.1. (http://cran.r-project.org).
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Results
The NOD2 variant IVS4+10 A>C (rs72796353) is not significantly
associated with susceptibility to Crohn’s disease or ulcerative colitis
Table 1 shows the demographic characteristics of the study population. A total of 1073
patients with CD, 464 patients with UC, and 719 controls with no history of IBD were
included in the analysis. The median disease duration was 14.6 years for CD patients and
13.0 years for UC patients. 11% of the CD patients had a positive family history of IBD com-
pared to 8% of the UC patients. There was no significant difference regarding the allele fre-
quencies of the NOD2 variant IVS4+10 A>C (rs72796353) in CD patients and controls
(allele frequency of 3.17% in CD patients vs. 2.85% in controls (p = 0.588, OR 1.12 [0.75–
1.65], Table 2), or UC patients and controls (allele frequency of 1.75% in patients with UC
vs. 2.85% in controls (p = 0.081, OR 0.60 [0.33–1.07], S3 Table). Allele frequencies of the
three main NOD2 mutations rs2066844, rs2066845 and rs2066847 in CD patients, UC
patients and controls, respectively are given in S4 Table).
The NOD2 variant IVS4+10 A>C is significantly associated with the
development of perianal fistulas
In a next step, we analyzed if the NOD2 variant IVS4+10 A>C is associated with a specific CD
phenotype. Table 2 shows the phenotypic characteristics of CD patients carrying the IVS4+10
A>C variant (AC/CC/-NOD2 group) compared to CD patients carrying no NOD2 variant
(none of the three main variants and no NOD2 IVS4+10 variant [13,26]; defined as NOD2
“wild-type” (WT)). No significant differences were seen for age at diagnosis, disease duration,
body mass index, use of immunosuppression, and disease location (Table 2).
More CD patients carrying the NOD2 variant IVS4+10 A>C suffered from penetrating CD
behaviour compared to patients with the NOD2WT (p = 0.014, OR 0.45 [0.24–0.85], Table 2).
Moreover, the NOD2 variant IVS4+10 A>C (rs72796353) was highly associated with the
Table 1. Demographic characteristics of the IBD study population.
Crohn’s disease Ulcerative colitis Controls
n = 1073 n = 464 n = 719
Gender
Male (%) 512 (47.7) 247 (53.2) 475 (66.1)
Female (%) 561 (52.3) 217 (46.8) 244 (33.9)
Age (yrs)
Mean ± SD 40.4 ± 14.2 43.2 ± 15.4 47.4 ± 9.2
Range (5–86) (8–91) (31–68)
Body mass index
Mean ± SD 23.1 ± 4.2 23.9 ± 4.5
Range (13.2–40.8) (15.2–53.6)
Age at diagnosis (yrs)
Mean ± SD 26.8 ± 12.0 30.7 ± 13.6
Range (2–78) (4–81)
Disease duration (yrs)
Mean ± SD 14.6 ± 9.4 13.0 ± 8.7
Range (0–50) (0–50)
Positive family history of IBD (%)
117 (10.9) 40 (8.6)
doi:10.1371/journal.pone.0116044.t001
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Table 2. CD phenotype stratified by the IVS4+10 A>C variant (rs72796353).
NOD2 rs72796353 (1) (2) (1) vs. (2) (1) vs. (2) (1) vs. (2)
genotype status AC/CC/-NOD2 NOD2 wild-type p-value OR 95% CI
n = 45 n = 593
Male sex (%)
24 (53%) 271 (45%) 0.282 1.40 [0.76–2.56]
Age at diagnosis (yrs, based on median OR+CI for > median)
Mean ± SD 25.2 ± 11.0 27.9 ± 12.1 0.632 1.16 [0.63–2.16]
Range (10–58) (4–78)
Disease duration (yrs, based on median OR+CI for > median)
Mean ± SD 17.3 ± 10.1 14.5 ± 9.3 0.163 0.65 [0.35–1.19]
Range (3–39) (0–42)
Body mass index (kg/m², based on median OR+CI for > median)
Mean ± SD 23.3 ± 4.5 23.3 ± 4.3 0.855 1.06 [0.55–2.08]
Range (15.9–32.7) (15.6–39.8)
Age at diagnosis
(n = 41) (n = 542)
16 years (A1) 9 (22%) 73 (14%) 0.142 0.56 [0.26–1.21]
17–40 years (A2) 28 (68%) 396 (73%) 0.533 1.22 [0.65–2.28]
> 40 years (A3) 4 (10%) 73 (14%) 0.499 1.44 [0.50–4.13]
Location
(n = 45) (n = 562)
Terminal ileum (L1) 8 (18%) 114 (20%) 0.974 1.01 [0.46–2.24]
Colon (L2) 8 (18%) 87 (16%) 0.450 0.73 [0.33–1.64]
Ileocolon (L3) 28 (62%) 350 (62%) 0.195 0.66 [0.35–1.24]
Upper GI (L4) 1 (2%) 11 (2%) 0.902 0.88 [0.11–6.96]
Any ileal involvement (L1+L3) 36 (81%) 464 (83%) 0.066 0.50 [0.23–1.05]
Behaviour 1
(n = 43) (n = 543)
Non-stricturing, Non-penetrat. (B1) 6 (14%) 166 (30%) 0.129 1.80 [0.84–3.83]
Stricturing (B2) 10 (23%) 145 (27%) 0.747 0.90 [0.46–1.74]
Penetrating (B3) 27 (63%) 232 (43%) 0.014 0.45 [0.24–0.85]
Use of immunosuppressive agents 2
(n = 45) (n = 561) 0.118 0.43 [0.15–1.24]
40 (89%) 450 (80%)
Surgery because of CD 3
(n = 41) (n = 540)
29 (71%) 274 (51%) 0.021 0.44 [0.22–0.89]
Fistulas
(n = 43) (n = 543)
27 (63%) 232 (43%) 0.014 0.45 [0.24–0.85]
Perianal fistulas
19/43 (44%) 71/544 (13%) 2.781 x 10−7 0.19 [0.10–0.35]
Stenosis
(n = 41) (n = 546)
(Continued)
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development of perianal fistulas in these patients (p = 2.78 x 10−7, OR 5.27 [2.75–10.12], OR
based on the NOD2 IVS4+10 A>C carriers; OR 0.19 [0.10–0.35], OR based on the NOD2
wildtype group; Table 2). In addition, the number of patients requiring CD-related surgery was
significantly higher in the AC/CC/-NOD2 group than in CD patients with the NOD2WT (p =-
0.022) whereas there were no significant differences seen between the two groups regarding
stricturing disease behaviour (Table 2).
The predictive power of the IVS4+10 A>C variant for fistulizing CD
disease behaviour is significantly higher in the absence of other NOD2
mutations
To analyze potential gene-dosage effects of the IVS4+10 A>C (rs72796353) variant in combi-
nation with the main CD-associated NOD2 mutants, p.Arg702Trp, p.Gly908Arg, and p.
Leu1007fsX1008 (rs2066844, rs2066845, and rs2066847), we compared rs72796353 minor (C)
allele carriers (n = 66) with wild-type (AA) patients (n = 1007, S5 Table).
There were no significant differences between the two groups regarding gender, age at diag-
nosis, disease duration, BMI, use of immunomodulators, stricturing disease behaviour and
CD-related surgery (S5 Table). However, significantly more minor allele carriers had perianal
fistulas, compared to wild-type subjects (33.4% vs. 12.5% with perianal fistulas, p = 6.031 x
10−6, S5 Table).
Interestingly, more rs72796353 minor allele carriers with no further NOD2mutant (AC/
CC/–NOD2 group) suffered from penetrating disease than carriers of the minor allele with an
additional main NOD2mutant (AC/+NOD2 group, 62.8% vs. 40%, p = 0.043, OR 0.32 [0.11–
0.97]). In addition, more CD patients in the AC/CC/–NOD2 group had perianal fistulas com-
pared to patients in the AC/+NOD2 group (44% vs. 10%, p = 0.016, S6 Table).
Discussion
Since the identification of NOD2 as the first CD susceptibility gene in 2001, the three main
NOD2 mutations p.Arg702Trp, p.Gly908Arg, and p.Leu1007fsX1008 still represent the most
strongly CD-associated variants [4,27,28]. In a study of Lesage et al. [13], the rare NOD2 vari-
ant IVS4+10 A>C (rs72796353) was only found in CD, suggesting its suitability as a predictor
for CD susceptibility.
In our cohort of 1073 well-phenotyped CD patients, we could demonstrate that the NOD2
variant IVS4+10 A>C is indeed a strong predictor for perianal fistulas in CD patients. This
Table 2. (Continued)
NOD2 rs72796353 (1) (2) (1) vs. (2) (1) vs. (2) (1) vs. (2)
genotype status AC/CC/-NOD2 NOD2 wild-type p-value OR 95% CI
n = 45 n = 593
24 (59%) 308 (56%) 0.841 0.94 [0.49–1.78]
Group (1), 43 CD patients heterozygous for the C allele of the rs72796353 variant and no further main NOD2 mutant, and 2 patients homozygous for the
C allele of the rs72796353 variant; group (2), CD patients without the IVS4+10 A>C variant and with no further main NOD2 mutant (NOD2 wild-type). ORs
are based on the NOD2 wild-type group (e.g., NOD2 wild-type status is protective against perianal fistulas).
1 Disease behaviour was defined according to the Montreal classification. A stricturing disease phenotype was defined as presence of stenosis without
penetrating disease. The diagnosis of stenosis was made surgically, endoscopically, or radiologically (using MR enteroclysis).
2 Immunosuppressive agents included azathioprine, 6-mercaptopurine, methotrexate, infliximab, and/or adalimumab.
3 Only surgery related to CD-specific problems (e.g., ileocecal resection, fistulectomy, colectomy, ileostomy) was included.
doi:10.1371/journal.pone.0116044.t002
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predictive power is significantly enhanced in patients carrying no other NOD2mutations,
emphasizing its applicability for disease course prediction in the absence of the well-established
three main NOD2mutants. However, we could not confirm the association between the NOD2
variant rs72796353 and CD susceptibility as suggested by the study of Lesage et al.[13].
In clinical practice, detection of the three main NOD2mutants has a great impact on disease
course prediction and is used in addition to clinical, endoscopic and radiological findings for
decisions regarding therapy [14,15,18,19,26,29]. Although the potential disease-causing effects
of several NOD2 variants were already investigated in functional assays on the protein level, the
effects of the IVS4+10 A>C variant rs72796353 have not yet been addressed in functional
investigations [30]. Lying close to the exon/intron boundary of exon 4, this SNP might influ-
ence the length of the encoded protein by creating an alternative splice site. To analyze the role
of the IVS4+10 A>C variant in IBD risk and phenotype, we analyzed this SNP in a large Ger-
man IBD patient cohort, thereby confirming that this NOD2 variant is more frequently present
in CD patients than in UC patients. Interestingly, only a few genetic studies investigated this
SNP in patients with IBD (S7 Table). In most studies, no significant difference was seen
between CD patients and controls, whereas a French study [13] found this variant in CD
patients but not in the control group (S7 Table). Our results were in accordance to the allele
frequencies determined in the HAPMAP project (S7 Table), confirming the predictive power
of our data set.
Regarding NOD2 haplotype associations, a recently published meta-analysis of 49 genetic
studies investigated the association between the risk of complicated CD conferred by the three
main mutants Arg702Trp, Gly908Arg, and p.Leu1007fsX1008 [19]. A total of 8.893 patients
with CD were included in the analysis, 2.897 of whom had NOD2mutations [19]. With the
presence of a single NOD2mutant, the risk of complicated disease was increased by 8%. In
compound heterozygous and homozygous carriers, the risk increase was 41% [19]. The surgery
risk increased by 58% with any of the three main NOD2mutants, whereas the risk of perianal
disease was not influenced [19]. These observations were recently confirmed by a Belgian single
center study [18]. Importantly, we could demonstrate that the minor C allele of rs72796353 is
highly associated with perianal disease in our cohort, strongly suggesting that this NOD2 vari-
ant is a genetic marker to detect CD patients with a high risk of developing perianal fistulas.
Several years ago, we and others [14,15] suggested a targeted, early-onset intensive therapy
for high-risk CD patients being homozygous carriers of the NOD2 frameshift mutation p.
Leu1007fsX1008 [14,15]. The recently published studies confirmed these recommendations in
high-risk patients with two NOD2mutations [18,19]. Likewise, rs72796353 could serve as a
predictor for perianal disease in CD patients in the absence of other NOD2mutations, thereby
increasing the set of reliable genetic markers for early disease course prediction, although larger
and prospective studies are needed to confirm the predictive power of rs72796353 in daily
clinical practice.
In conclusion, there was no significant disease association of the NOD2 variant IVS4+10
A>C with CD and UC. However, in the absence of other NOD2mutations, the NOD2 variant
IVS4+10 A>C was significantly associated with perianal fistulas in CD patients, suggesting the
IVS4+10 A>C variant as a novel predictor for perianal disease in CD.
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S3 Table. Given are minor allele frequencies (MAF) of the NOD2 variant rs72796353 (IVS4
+10 A>C) in patients with Crohn’s disease, ulcerative colitis as well as in controls.Minor
allele frequencies, allelic test P-values, and odds ratios (OR, shown for the minor allele) with
95% confidence intervals (CI) are depicted for both the CD and UC case-control cohorts.
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S4 Table. Given are allele frequencies of the three main NOD2 mutations, rs2066844,
rs2066845, and rs2066847 in patients with Crohn’s disease and, ulcerative colitis as well as
in controls.Minor allele frequencies (MAF), allelic test P-values, and odds ratios (OR, shown
for the minor allele) with 95% confidence intervals (CI) are depicted for both the CD and UC
case-control cohorts. Details on the phenotypes of a subgroup of these patients were reported
in previous studies [17, 18].
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S5 Table. Association between the rs72796353 genotype and CD disease characteristics
based on the Montreal classification [27]. For each variable, the number of patients included
is given. 1Disease behaviour was defined according to the Montreal classification [27]. A stric-
turing disease phenotype was defined as presence of stenosis without penetrating disease. ORs
(odds ratios) are shown for the AA allele. Diagnosis of stenoses was made surgically, endoscop-
ically, or radiologically (using MR enteroclysis).2 Immunosuppressive agents included azathio-
prine, 6-mercaptopurine, methotrexate, infliximab, and/or adalimumab. 3 Only surgery related
to CD-specific problems (e.g., ileocecal resection, fistulectomy, colectomy, ileostomy) was
included.
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plus one of the main NOD2mutations (AC/+NOD2) and in CD patients carrying the SNP
rs72796353 without one of the main NOD2mutations (AC/-NOD2). For each variable, the
number of patients included is given. 1Disease behaviour was defined according to the Mon-
treal classification [27]. A stricturing disease phenotype was defined as presence of stenosis
without penetrating disease. The diagnosis of stenosis was made surgically, endoscopically, or
radiologically (using MR enteroclysis).2 Immunosuppressive agents included azathioprine,
6-mercaptopurine, methotrexate, infliximab, and/or adalimumab. 3 Only surgery related to
CD-specific problems (e.g., ileocecal resection, fistulectomy, colectomy, ileostomy) was
included.
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S7 Table. Comparison of the observed allele frequencies of rs72796353 with data published
in the literature (Fishers exact test). C allele frequencies in patients with CD were similar to
the data reported by the HAPMAP project. Interestingly, they were significantly different com-
pared to those published by Lesage et al. [16] and Tukel et al. [24] In the French study,
rs72796353 was not found in controls, whereas Tukel et al. [24] observed significant lower
allele frequencies in Jewish families compared to our German population.
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